菲利华：10月23日召开董事会会议

Group 1 - The core point of the article is that Feilihua (SZ 300395) held its 23rd meeting of the 6th board of directors on October 23, 2025, to review the third quarter report for 2025 [1] - For the first half of 2025, Feilihua's revenue composition shows that the non-metallic mineral products industry accounted for 99.7% of its total revenue, while other businesses contributed 0.3% [1] - As of the time of reporting, Feilihua's market capitalization is 40.9 billion yuan [1] Group 2 - The article also highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a hot secondary market in biomedicine, while the primary market is facing fundraising challenges [1]